Cobalt Challenges Patents For AstraZeneca's Crestor

Law360, New York (November 1, 2007, 12:00 AM EDT) -- Cobalt Pharmaceuticals Inc. is seeking U.S. regulatory approval to make and sell a generic version of Astrazeneca PLC's cholesterol drug Crestor, claiming that two patents for the drug, which had U.S. sales of $696 million in the first half of 2007, are invalid, not infringed or unenforceable.

AstraZeneca received a notification letter from Canada-based generics maker Cobalt on Tuesday, saying that Cobalt submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration looking for authorization to market generic rosuvastatin calcium tablets before the...
To view the full article, register now.